SELLAS Life Sciences Group (NasdaqCM:SLS) has seen its one-year price target revised to $10.20 per share, reflecting a 15.38% increase from the previous estimate of $8.84 dated April 12, 2026. The current price target represents a potential upside of 108.80% compared to its latest closing price of $4.88.
Institutional sentiment shows 135 funds reporting positions in SELLAS, down by 18 funds or 11.76% from the previous quarter. However, the average portfolio weight for these funds increased by 62.97% to 0.03%. Notably, Geode Capital Management increased its holdings by 26.42% to 3,077K shares, while Millennium Management saw a significant rise of 77.32%, now holding 1,388K shares. The put/call ratio stands at 0.06, indicating a bullish outlook for the stock.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
